SimBioSys Gains FDA Clearance for TumorSight Viz in Breast Cancer Surgery

Jul 15, 2025
SimBioSys has received its third FDA clearance for TumorSight Viz, enhancing AI-driven precision in breast cancer surgery, as announced in a press release.
SimBioSys Gains FDA Clearance for TumorSight Viz in Breast Cancer Surgery

SimBioSys has secured its third FDA 510(k) clearance for TumorSight Viz, an AI-powered platform designed to enhance precision in breast cancer surgery, announced in a press release. This latest version, TumorSight Viz 1.3, introduces advanced features such as superior AI-driven segmentation and faster case processing, which aim to improve preoperative planning and streamline surgical workflows.

The platform converts standard breast MRI into intuitive 3D visualizations, supporting more informed surgical decision-making. With its new capabilities, TumorSight Viz 1.3 enhances surgeon usability and integrates seamlessly into existing workflows, offering same-day insights for timely patient consultations.

SimBioSys emphasizes that TumorSight Viz 1.3 is clinically validated, with studies showing strong concordance with radiologist annotations and consistent performance across multiple institutions. This clearance marks a significant step in providing surgeons with tools that offer greater clarity and control in breast cancer surgery, ultimately aiming to improve patient outcomes.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.